Figure 1

Frequency and severity of principal adverse events in patients with metastatic RCC treated with bevacizumab plus IFN or with sunitinib (Escudier et al, 2007; Motzer et al, 2007; Negrier et al, 2008). IFN=interferon-α2a; NR=not reported; RCC=renal call carcinoma.